This trial aims to the use of the patient's own heart stem cells in ischemic heart failure. The trial is being conducted at the Royan Institute in Teheran and proposes to recruit 50 patients between December 2012 and December 2015. Participants will be randomly allocated to two groups. The experimental group will receive their own heart stem cells administered via an intracoronary artery (presumably by coronary artery catheterisation). It is unclear from the NIH registry how the cells are harvested and/or expanded in the laboratory. It is also unclear as to how the placebo is delivered in the control group. All participants will be monitored for complications and assessed for changes in their clinical condition including left ventricular ejection fraction.